WALDENSTRÖM MAKROGLOBULİNEMİLİ HASTALARIMIZIN KLİNİK ÖZELLİKLERİ VE PROGNOZ: TEK MERKEZ DENEYİMİ / CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH WALDENSTRÖM'S MACROGLOBULINEMIA: SINGLE CENTER EXPERIENCE
Abstract
Özet: Waldenström Makroglobulinemisi (WM) immunglobulin (Ig)M protein artışı ile karakterize lenfoplazmasitik bir lenfomadır. Anemi, trombositopeni, hepatosplenomegali (HSM), lenfadenopati (LAP) ve nadiren de hipervizkosite hastalığın klinik özelliklerindendir. Yaş, hemoglobin düzeyi, trombosit sayısı, beta-2 mikroglobulin ve monoklonal IgM miktarı prognoz üzerine etkili faktörlerdendir. Hastalarımızın %84’ünde HM, %47’inde SM ve %63’ünde LAP saptandı. En sık başvuru semptomu %47,4 ile halsizlik, yorgunluktu. Hastalarımızın yaklaşık yarısı yüksek risk skoruna sahip olup ortalama yaşam süreleri 67 ay idi.
ANAHTAR KELİMELER: Waldenström makroglobulinemisi, prognoz.
CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH WALDENSTRÖM'S MACROGLOBULINEMIA: SINGLE CENTER EXPERIENCE
Abstract: Waldenström’s Macroglobulinemia (WM) is a lymphoplasmacytic lymphoma associated with a monoclonal immunoglobulin (Ig)M protein. The clinical manifestations of the disorder are anemia, thrombocytopenia, hepato-splenomegaly (HSM), lymphadenopathy (LAP), and rarely hyperviscosity. Age, hemoglobin level, platelet count, beta-2 microglobulin, and monoclonal IgM concentrations are characteristics required for prognosis. The clinical manifestations in our patients were hepatomegaly 84%, splenomegaly 47%, and lymphadenopathy 63%. The most common presenting symptom was fatigue. Our patients’ risk scores were high and their overall survival was 67 months.
KEY WORDS: Waldenström ‘s Macroglobulinemia, prognosis
Details
| Primary Language | English |
|---|---|
| Journal Section | ORİJİNAL MAKALE |
| Authors | |
| Publication Date | December 25, 2015 |
| Published in Issue | Year 2015 Volume: 37 Issue: 2 |